Search research articles
Contact Us
Filters
Showing results (81-90 of 189) with videos related to
Page
of 19
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 6, 2000
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)
M Merad, E Angevin, J Wolfers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
E Angevin, D Valteau-Couanet, F Farace, et al.
International Journal of Cancer
|
July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma
F Farace, E Angevin, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 22, 2012
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, T Eisen, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, et al.
Intensive Care Medicine
|
August 1, 1995
Safety of tracheotomy in neutropenic patients: a retrospective study of 26 consecutive cases
F Blot, G Nitenberg, M Guiguet, et al.
European Cytokine Network
|
June 12, 2001
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial
G Gravis, M Mousseau, J Y Douillard, et al.
European Cytokine Network
|
August 1, 1990
In vivo activation of LAK cells during systemic IL-2 therapy
P Lang, I Vitté-Mony, F Farace, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2018
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
F Ruatta, L Derosa, B Escudier, et al.
Page
of 19
Search research articles
Search
Showing results (81-90 of 189) with videos related to
Sort By:
Page
of 19
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 6, 2000
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)
M Merad, E Angevin, J Wolfers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
October 1, 1995
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
E Angevin, D Valteau-Couanet, F Farace, et al.
International Journal of Cancer
|
July 9, 1993
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma
F Farace, E Angevin, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 22, 2012
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, T Eisen, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2016
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, et al.
Intensive Care Medicine
|
August 1, 1995
Safety of tracheotomy in neutropenic patients: a retrospective study of 26 consecutive cases
F Blot, G Nitenberg, M Guiguet, et al.
European Cytokine Network
|
June 12, 2001
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial
G Gravis, M Mousseau, J Y Douillard, et al.
European Cytokine Network
|
August 1, 1990
In vivo activation of LAK cells during systemic IL-2 therapy
P Lang, I Vitté-Mony, F Farace, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2018
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
F Ruatta, L Derosa, B Escudier, et al.
Page
of 19